We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

By LabMedica International staff writers
Posted on 29 Nov 2023
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating bacterial colonies with antibiotics, a process that is notably time-consuming, often taking several days to gauge bacterial resistance to a spectrum of antibiotics. This delay poses a significant challenge in urgent medical situations, like sepsis, where prompt treatment is crucial. As a result, clinicians are often compelled to either rely on their clinical judgment to prescribe specific antibiotics or administer a broad-spectrum antibiotic regimen. However, the use of ineffective antibiotics can exacerbate infections and potentially lead to increased AMR in the community. Now, researchers have reported significant progress in developing a rapid antimicrobial susceptibility test that can deliver results in as little as 30 minutes, marking a huge improvement over current standard methods.

A team of researchers from the University of Oxford (Oxford, UK) has created a method combining fluorescence microscopy with artificial intelligence (AI) to detect AMR. This technique involves training deep-learning models to scrutinize images of bacterial cells and identify structural changes when exposed to antibiotics. The method proved successful with various antibiotics, demonstrating a minimum accuracy of 80% on a per-cell analysis. The team applied this method to various clinical strains of E. coli, each exhibiting different resistance levels to the antibiotic ciprofloxacin. Impressively, the deep-learning models consistently and accurately identified antibiotic resistance, achieving results at least tenfold faster than current leading clinical methods.

With further development, this rapid testing method has the potential to enable more precise antibiotic treatments, reducing treatment durations, lessening side effects, and helping to curb the growth of AMR. The research team envisions future adaptations of this model for detecting resistance in clinical samples to a broader range of antibiotics. Their goal is to enhance the speed and scalability of this method for clinical application, as well as to modify it for use with various types of bacteria and antibiotics.

“Antibiotics that stop the growth of bacterial cells also change how cells look under a microscope, and affect cellular structures such as the bacterial chromosome,” said Achillefs Kapanidis, Professor of Biological Physics and Director of the Oxford Martin Program on Antimicrobial Resistance Testing. “Our AI-based approach detects such changes reliably and rapidly. Equally, if a cell is resistant, the changes we selected are absent, and this forms the basis for detecting antibiotic resistance.”

Related Links:
University of Oxford

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Gastrointestinal Panel
Xpert® GI Panel
POC Immunoassay Analyzer
Procise DX

Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more